Lyra therapeutics reports third quarter 2024 financial results and provides corporate update

Watertown, mass., nov. 12, 2024 (globe newswire) --   lyra therapeutics, inc.  (nasdaq: lyra) (“lyra” or the “company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory sinonasal implants for the treatment of chronic rhinosinusitis (crs), today reported its financial results for the third quarter ended september 30, 2024 and provided a corporate update.
LYRA Ratings Summary
LYRA Quant Ranking